AU2001255195B2 - Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases - Google Patents

Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases Download PDF

Info

Publication number
AU2001255195B2
AU2001255195B2 AU2001255195A AU2001255195A AU2001255195B2 AU 2001255195 B2 AU2001255195 B2 AU 2001255195B2 AU 2001255195 A AU2001255195 A AU 2001255195A AU 2001255195 A AU2001255195 A AU 2001255195A AU 2001255195 B2 AU2001255195 B2 AU 2001255195B2
Authority
AU
Australia
Prior art keywords
compound
age
advanced glycation
phenoxy
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2001255195A
Other languages
English (en)
Other versions
AU2001255195A1 (en
Inventor
Samuel Rahbar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,703 external-priority patent/US6337350B1/en
Application filed by City of Hope filed Critical City of Hope
Publication of AU2001255195A1 publication Critical patent/AU2001255195A1/en
Application granted granted Critical
Publication of AU2001255195B2 publication Critical patent/AU2001255195B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001255195A 2000-04-05 2001-03-27 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases Expired AU2001255195B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/543,703 US6337350B1 (en) 1999-04-05 2000-04-05 Inhibitors of formation of advanced glycation endproducts (AGEs)
US09/543,703 2000-04-05
US55991300A 2000-04-28 2000-04-28
US09/559,913 2000-04-28
US09/626,859 US6589944B1 (en) 1999-04-05 2000-07-27 Breakers of advanced glycation endproducts
US09/626,859 2000-07-27
PCT/US2001/009645 WO2001076584A2 (en) 2000-04-05 2001-03-27 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases

Publications (2)

Publication Number Publication Date
AU2001255195A1 AU2001255195A1 (en) 2002-01-10
AU2001255195B2 true AU2001255195B2 (en) 2005-04-28

Family

ID=27415415

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001255195A Expired AU2001255195B2 (en) 2000-04-05 2001-03-27 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
AU5519501A Pending AU5519501A (en) 2000-04-05 2001-03-27 Novel breakers of advanced glycation endproducts

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU5519501A Pending AU5519501A (en) 2000-04-05 2001-03-27 Novel breakers of advanced glycation endproducts

Country Status (6)

Country Link
US (1) US6589944B1 (enExample)
EP (1) EP1272172A2 (enExample)
JP (1) JP2003530346A (enExample)
AU (2) AU2001255195B2 (enExample)
CA (1) CA2405411A1 (enExample)
WO (1) WO2001076584A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030133B2 (en) * 1999-04-05 2006-04-18 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
DE10158076B4 (de) * 2001-11-27 2005-09-01 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitungen mit einem Gehalt an Aryl-Ureido-Verbindungen und ihre Verwendung
EP2269601A1 (en) * 2003-10-27 2011-01-05 City of Hope LR-9, LR-74 and LR-90 for use in treating complications resulting from diabetes
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
KR101323411B1 (ko) 2004-08-03 2013-10-30 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
FR2883873B1 (fr) 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US8053449B2 (en) * 2005-10-05 2011-11-08 Cell Viable Corporation Method for inhibiting AGE complex formation
US8580854B2 (en) * 2005-11-09 2013-11-12 City Of Hope Methods of suppression of rage gene expression and rage triggered inflammatory genes by selected age-inhibitors
KR20090008459A (ko) 2006-05-05 2009-01-21 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법
CA2662430A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
WO2008033124A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
RU2486902C2 (ru) * 2007-01-16 2013-07-10 АЙПИИНТЛ, ЭлЭлСи Новая композиция для лечения метаболического синдрома
DE102007041232A1 (de) 2007-08-30 2009-03-05 Henkel Ag & Co. Kgaa Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs
PL2158210T3 (pl) 2007-06-14 2016-08-31 Galactica Pharmaceuticals Inc Białka fuzyjne RAGE
US8124655B2 (en) * 2007-06-15 2012-02-28 City Of Hope Use of LR-90 and LR-102 to overcome insulin resistance
FR2918570B1 (fr) * 2007-07-09 2012-10-05 Engelhard Lyon DIGLYCATION DES AGEs.
DE102007054653A1 (de) 2007-11-14 2009-05-20 Henkel Ag & Co. Kgaa Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP2408434A4 (en) * 2009-03-16 2013-11-27 Ipintl Llc TREATMENT OF MORBUS ALZHEINER AND OSTEOPOROSE AND REDUCTION OF AGING
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
WO2012103523A2 (en) * 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007560A1 (en) * 1990-10-31 1992-05-14 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
AU763750B2 (en) * 1999-04-05 2003-07-31 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (AGE's)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (enExample) * 1980-03-20 1982-03-11
JP4294120B2 (ja) * 1998-05-12 2009-07-08 株式会社フジモト・ブラザーズ 抗炎症用薬剤組成物
JP2002543118A (ja) 1999-04-29 2002-12-17 シティ・オブ・ホープ ペントキシフィリン、ピオグリタゾンおよびメトフォルミンは、後期糖化最終生成物（ａｇｅ）の形成の阻害剤である

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007560A1 (en) * 1990-10-31 1992-05-14 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
AU763750B2 (en) * 1999-04-05 2003-07-31 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (AGE's)

Also Published As

Publication number Publication date
EP1272172A2 (en) 2003-01-08
WO2001076584A2 (en) 2001-10-18
AU5519501A (en) 2001-10-23
CA2405411A1 (en) 2001-10-18
JP2003530346A (ja) 2003-10-14
WO2001076584A3 (en) 2002-06-27
US6589944B1 (en) 2003-07-08

Similar Documents

Publication Publication Date Title
AU2001255195B2 (en) Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
US6787566B2 (en) Breakers of advanced glycation endproducts
AU2001255195A1 (en) Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
Rahbar et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation
EP1165064B1 (en) Novel inhibitors of formation of advanced glycation endproducts (age's)
US6693106B2 (en) Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)
US6605642B2 (en) Inhibitors of formation of advanced glycation endproducts (AGES)
AU2002252184A1 (en) Novel inhibitors of formation of advanced glycation endproducts (AGEs)
EP1594492B1 (en) Novel inhibitors of formation of advanced glycation endproducts (ages)
US8034966B1 (en) Phenoxyisobutyric acid compounds and methods for synthesis
US20140371316A1 (en) Derivatives of phenoxyisobutyric acid

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired